share_log

180 Life Sciences | 8-K: Current report

180 Life Sciences | 8-K: Current report

180 Life Sciences | 8-K：重大事件
美股SEC公告 ·  03/14 08:34

Moomoo AI 已提取核心信息

180 Life Sciences Corp. has announced that it has regained compliance with the Nasdaq's minimum bid price requirement, as per a notification received from The Nasdaq Stock Market LLC on March 13, 2024. The company's common stock had previously failed to maintain the required minimum bid price of $1.00 over a 30-day period, as stated by Nasdaq Listing Rule 5550(a)(2). However, the closing bid price of the company's common stock has now been at or above $1.00 for 10 consecutive business days. Despite this positive development, 180 Life Sciences remains non-compliant with Nasdaq's minimum stockholders' equity requirement, reporting a stockholders' deficit of ($149,327) for the quarter ended September 30, 2023, which falls short of the Nasdaq Capital Market's requirement of at least $2,500,000 in stockholders' equity. The company is exploring various options to address this issue and is hopeful to regain compliance within the granted period. The press release regarding the regained compliance with the bid price requirement was filed on March 14, 2024.
180 Life Sciences Corp. has announced that it has regained compliance with the Nasdaq's minimum bid price requirement, as per a notification received from The Nasdaq Stock Market LLC on March 13, 2024. The company's common stock had previously failed to maintain the required minimum bid price of $1.00 over a 30-day period, as stated by Nasdaq Listing Rule 5550(a)(2). However, the closing bid price of the company's common stock has now been at or above $1.00 for 10 consecutive business days. Despite this positive development, 180 Life Sciences remains non-compliant with Nasdaq's minimum stockholders' equity requirement, reporting a stockholders' deficit of ($149,327) for the quarter ended September 30, 2023, which falls short of the Nasdaq Capital Market's requirement of at least $2,500,000 in stockholders' equity. The company is exploring various options to address this issue and is hopeful to regain compliance within the granted period. The press release regarding the regained compliance with the bid price requirement was filed on March 14, 2024.
根据纳斯达克股票市场有限责任公司于2024年3月13日收到的通知，180生命科学公司宣布已恢复遵守纳斯达克的最低出价要求。根据纳斯达克上市规则5550（a）（2）的规定，该公司的普通股此前未能在30天内维持1.00美元的最低出价。但是，该公司普通股的收盘价现已连续10个工作日达到或超过1.00美元。尽管取得了这一积极进展，180 Life Sciences仍未遵守纳斯达克的最低股东权益要求，报告称，截至2023年9月30日的季度股东赤字为（149,327美元），低于纳斯达克资本市场对至少250万美元股东权益的要求。该公司正在探索各种选择来解决这个问题，并希望在规定的期限内恢复合规。关于恢复遵守投标价格要求的新闻稿已于2024年3月14日提交。
根据纳斯达克股票市场有限责任公司于2024年3月13日收到的通知，180生命科学公司宣布已恢复遵守纳斯达克的最低出价要求。根据纳斯达克上市规则5550（a）（2）的规定，该公司的普通股此前未能在30天内维持1.00美元的最低出价。但是，该公司普通股的收盘价现已连续10个工作日达到或超过1.00美元。尽管取得了这一积极进展，180 Life Sciences仍未遵守纳斯达克的最低股东权益要求，报告称，截至2023年9月30日的季度股东赤字为（149,327美元），低于纳斯达克资本市场对至少250万美元股东权益的要求。该公司正在探索各种选择来解决这个问题，并希望在规定的期限内恢复合规。关于恢复遵守投标价格要求的新闻稿已于2024年3月14日提交。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间